LECIP
15.1.2019 13:02:12 CET | Business Wire | Press release
LECIP ARCONTIA AB , a Swedish producer of contactless smart card products and solutions for Automated Fare Collection System (AFC), today announces the launch of its new on-board validator for electronic fare collection schemes in public transport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005048/en/
The LV-700 series is the latest addition to LECIP ARCONTIA’s portfolio of contactless smart card readers and terminals for transport ticketing. The series is designed for fast and smooth cashless payment with a high-speed processor and large capacity memory for demanding ticket data processing. It supports various types of media such as ISO14443 A/B standard, EMV contactless (L1), QR and Aztec/2D bar code and ISO 18092 (NFC Forum Reader/Writer mode).
Thanks to state-of-the-art design, the LV-700 is made to easily and quickly attach and detach for efficient maintenance. The LV-700 houses a 5.7’’ colour touch screen display for optimum viewing and easy menu navigation. The series is robust and tamper resistant, offering IK10 and IP54 ratings and high resistance against chemical attack.
For easy integration, the LV-700 series comes with an extensive Software Development Kit (SDK) and LECIP ARCONTIA’s software libraries giving great time efficiency for developers.
“The global trend in payments is cashless and we are proud to introduce our latest LV-700 validators. The LV-700 series can help transport operators with various methods of cashless payments, enabling seamless payment for passengers and increasing service levels,” says Yasuhiro Ohara, president of LECIP ARCONTIA.
The LV-700 validator will be showcased at the upcoming Transport Ticketing Global in London, UK on January 29-30. To find out more, please visit us at stand A10.
About LECIP ARCONTIA AB
LECIP ARCONTIA AB , a subsidiary of LECIP HOLDINGS CORPORATION of Gifu, Japan, operates globally to deliver contactless smart card products and solutions for Automated Fare Collection System (AFC).
Since 1990s, we have supplied companies worldwide with our smart card reader technology. Today, we develop and distribute smart card readers and terminals used in over 40 countries. Our focus is to deliver reliable, high quality contactless smart card products, and implement software services featuring the latest technology and market requirements in e-ticketing and payment. LECIP ARCONTIA's head office is based in Gothenburg, Sweden.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005048/en/
Contact:
Lisa Olofsson Sales Assistant LECIP ARCONTIA AB E-mail: lisa.olofsson@lecip.se
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom